Paget disease of the nipple
diseaseOn this page
Also known as mammary Paget diseasenipple Paget's diseasePaget disease of the breastPaget's disease of nipplePaget's disease of the nipplePaget's disease, mammaryPD
Summary
Paget disease of the nipple (MONDO:0015873) is a disease and 10 clinical trials. Top therapeutic interventions include dexmedetomidine hydrochloride, methoxy polyethylene glycol-epoetin beta, and torsemide. A subtype of mammary Paget disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Clinical trials: 10
Clinical features
Epidemiology
Prevalence records
24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.51 | Europe | Validated |
| Annual incidence | <1 / 1 000 000 | 0.065 | Finland | Validated |
| Annual incidence | <1 / 1 000 000 | 0.096 | Poland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.179 | Austria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.433 | Belgium | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.235 | Bulgaria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.192 | Croatia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.287 | Czech Republic | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.434 | Estonia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.29 | Germany | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.682 | Iceland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.487 | Ireland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.421 | Italy | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.254 | Latvia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.215 | Lithuania | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.345 | Malta | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.709 | Norway | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.209 | Portugal | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.21 | Slovakia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.457 | Slovenia | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Paget disease of the nipple |
| Mondo ID | MONDO:0015873 |
| Orphanet | 180275 |
| ICD-11 | 1295910447 |
| NCIT | C3301 |
| SNOMED CT | 403946000 |
| UMLS | C1704323 |
| MedGen | 352830 |
| GARD | 0007303 |
| MedDRA | 10033367 |
| NORD | 1544 |
| Is cancer (heuristic) | no |
Also known as: mammary Paget disease · nipple Paget’s disease · Paget disease of the breast · Paget disease of the nipple · Paget’s disease of nipple · Paget’s disease of the nipple · Paget’s disease, mammary · PD
Disease family
This is a subtype of mammary Paget disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › mammary Paget disease › Paget disease of the nipple
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 10.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 3 |
| Not specified | 3 |
| PHASE1 | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00455143 | PHASE4 | TERMINATED | Cognitive Protection - Dexmedetomidine and Cognitive Reserve |
| NCT00561678 | PHASE4 | COMPLETED | Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve |
| NCT01807481 | PHASE4 | UNKNOWN | Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD |
| NCT07015671 | PHASE3 | COMPLETED | Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects |
| NCT01849250 | PHASE2 | COMPLETED | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors |
| NCT07195825 | PHASE1 | RECRUITING | A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson’s Disease |
| NCT03942458 | PHASE1 | COMPLETED | Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19 |
| NCT05810454 | Not specified | NOT_YET_RECRUITING | iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS |
| NCT00105131 | Not specified | COMPLETED | Genetic Characterization of Parkinson’s Disease |
| NCT03021408 | Not specified | UNKNOWN | Effectiveness of Different Approaches for the Rehabilitation of Gait in Patients With Parkinson’s Disease |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE | 4 | 2 |
| METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | 4 | 1 |
| TORSEMIDE | 4 | 1 |
| DOCONEXENT | 3 | 1 |
| SUMECIGREL | 2 | 1 |
| CHEMBL4439413 | 0 | 1 |